
Legal and financial questions of Pfizer-Novo-Metsera
Shareholder Primacy
00:00
Why Novo's Bid Looked Financially Superior
Hosts compare Novo's higher cash and CVR offer to Pfizer's and discuss absolute valuation differences.
Play episode from 07:54
Transcript


